Ph 2: Carfilzomib & lenalidomide-based treatment for newly diagnosed primary plasma cell leukemia
NCT02406144: Phase 3 - GEM2014MAIN - Maintenance Len, Dex VS Len, Dex. & MLN9708 After ASCT NDMM
NCT02197221: Phase 3: Bortezomib-Melphalan Conditioning Regimen vs Melphalan - Frontline Transplant
NCT02046070: Phase 2 to Evaluate the Oral Ixazomib (MLN9708) With Cyclophosphamide & Dex Myeloma
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT
NCT02195479 : A Phase 3, Study of Bortezomib, Melphalan, Prednisone & Daratumumab ALCYONE trial
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
NCT02315716: Phase 2 -Carfilzomib/Cyclophosphamide/Dex With Maint. Carfilzomib - NDMM Cardamon Study
NCT02322320: Phase 3 - Continued, Long-Term Follow-Up and Lenalidomide Maint. (BMT CTN 07LT)
NCT02312258: Phase 3: TOURMALINE-MM4 - Oral Ixazomib Maintenance Therapy in NDMM-TIE
NCT02203643: Phase 2 - Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex - NDMM - FORTE
NCT01863550: Phase 3 - Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in NDMM
NCT01816971: Phase 2 - Carfilzomib, Lenalidomide, and Dexamethasone Before and After ASCT NDMM
NCT01980589: Phase 1b: Study of Carfilzomib, Cyclophosphamide and Dexamethasone in NDMM CHAMPION 2
NCT01782963: Phase 2 - Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM) (RVD Lite)
NCT01857115: Phase 1/2: EMN - Study of Wkly Carfilzomib, Cyclophosphamide and Dexamethasone In NDMM
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid
NCT02002598 : Phase 1 /2 -Carfilzomib + Bendamustine and Dex in New MM
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM